<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02355119</url>
  </required_header>
  <id_info>
    <org_study_id>GIP-2</org_study_id>
    <nct_id>NCT02355119</nct_id>
  </id_info>
  <brief_title>Italian Multicenter Study Comparing FOLFOXIRI Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer</brief_title>
  <acronym>GIP-2</acronym>
  <official_title>Phase III Italian Multicenter Study Comparing the Combination of 5-fluorouracil/Folinic Acid, Oxaliplatin and Irinotecan (Folfoxiri) Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero, Universitaria Pisana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliero, Universitaria Pisana</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with resected pancreatic cancer who fulfill the selection criteria will be&#xD;
      randomized to receive one of the two treatment arms for a period of 6 months: Gemcitabine,&#xD;
      the standard arm, or FOLFOXIRI (the combination of 5-Fluorouracil/Folinic Acid, Oxaliplatin&#xD;
      and Irinotecan), the experimental arm.&#xD;
&#xD;
      A total of 310 patients will be enrolled in about 50 Italian centers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with resected stage I-III pancreatic cancer who fulfill the selection criteria will&#xD;
      be randomized to receive one of the two treatment arms for a period of 6 months: Gemcitabine,&#xD;
      the standard arm, or FOLFOXIRI (the combination of 5-Fluorouracil/Folinic Acid, Oxaliplatin&#xD;
      and Irinotecan), the experimental arm.&#xD;
&#xD;
      A total of 310 patients will be enrolled in about 50 Italian centers. All the patients will&#xD;
      be followed up during and after the treatment until disease progression and death or for a&#xD;
      minimum of 60 months.&#xD;
&#xD;
      Main objective:&#xD;
&#xD;
      To show an increase in disease-free survival with an HR of 0.70 for patients enrolled into&#xD;
      the experimental arm compared with standard arm.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      To show an increase in overall survival with an HR of 0.70 for patients enrolled into the&#xD;
      experimental arm compared with standard arm.&#xD;
&#xD;
      To show the tolerability of the experimental treatment in this setting.&#xD;
&#xD;
      Principal inclusion criteria:&#xD;
&#xD;
        -  histological diagnosis of pancreatic cancer&#xD;
&#xD;
        -  surgical resection with curative intent within 10 weeks before of enrollment (stage&#xD;
           I-III)&#xD;
&#xD;
        -  absence of evidence of metastases (cM0)&#xD;
&#xD;
        -  age 18-75&#xD;
&#xD;
        -  ECOG performance status 0-1&#xD;
&#xD;
        -  adequate bone marrow, liver and renal function&#xD;
&#xD;
        -  written informed consent&#xD;
&#xD;
      Principal exclusion criteria:&#xD;
&#xD;
        -  evidence of metastases&#xD;
&#xD;
        -  CA19.9 higher than 2.5 x ULN (upper limit of normal range)&#xD;
&#xD;
        -  precedent chemotherapy or radiotherapy&#xD;
&#xD;
        -  coexisting malignancies&#xD;
&#xD;
        -  relevant coexisting diseases that could contraindicate the participation to the study&#xD;
&#xD;
        -  hypersensitivity/intolerance to the drugs in study&#xD;
&#xD;
        -  pregnancy or breastfeeding&#xD;
&#xD;
        -  neurotoxicity of grade &gt; 1&#xD;
&#xD;
        -  malabsorption syndrome&#xD;
&#xD;
      Primary end-point:&#xD;
&#xD;
      Disease-free survival, defined as the time from enrollment to the evidence of progression of&#xD;
      disease or death.&#xD;
&#xD;
      Secondary end-points:&#xD;
&#xD;
      Overall survival, defined as the time from enrollment to the evidence of death. Toxicity,&#xD;
      defined according to NCI-CTC&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>up to 1 year after last patient in</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 2 years after last patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>up to 28 weeks from treatment beginning</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine 1000 mg/sqm on days 1,8,15 every 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFOXIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOXIRI</intervention_name>
    <description>Combination of 5-Fluorouracil/Folinic Acid, Irinotecan, Oxaliplatin</description>
    <arm_group_label>FOLFOXIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>Gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histological diagnosis of pancreatic cancer&#xD;
&#xD;
          -  surgical resection with curative intent within 10 weeks before of enrollment (stage&#xD;
             I-III)&#xD;
&#xD;
          -  absence of evidence of metastases (cM0)&#xD;
&#xD;
          -  age 18-75&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  adequate bone marrow, liver and renal function&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  evidence of metastases&#xD;
&#xD;
          -  CA19.9 higher than 2.5 x ULN (upper limit of normal range)&#xD;
&#xD;
          -  precedent chemotherapy or radiotherapy&#xD;
&#xD;
          -  coexisting malignancies&#xD;
&#xD;
          -  relevant coexisting diseases that could contraindicate the participation to the study&#xD;
&#xD;
          -  hypersensitivity/intolerance to the drugs in study&#xD;
&#xD;
          -  pregnancy or breastfeeding&#xD;
&#xD;
          -  neurotoxicity of grade &gt; 1&#xD;
&#xD;
          -  malabsorption syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrico Vasile, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero, Universitaria Pisana</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Enrico Vasile, MD, PhD</last_name>
    <email>envasile@tin.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrico Vasile, MD, PhD</last_name>
      <phone>+39 050 992466</phone>
      <email>envasile@tin.it</email>
    </contact>
    <investigator>
      <last_name>Enrico Vasile, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>January 20, 2015</study_first_submitted>
  <study_first_submitted_qc>February 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2015</study_first_posted>
  <last_update_submitted>February 3, 2015</last_update_submitted>
  <last_update_submitted_qc>February 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero, Universitaria Pisana</investigator_affiliation>
    <investigator_full_name>Enrico Vasile</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

